

## ABSTRACT

Methods Mol Biol. 2022;2423:123-140. doi: 10.1007/978-1-0716-1952-0\_13.  
Online 2022 Feb 1.

### **Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy.**

Maurya A(1), Patel UK(1), Yadav JK(1), Singh VP(1), Agarwal A(2).

#### Author information:

(1)Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

(2)Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India. agarwal.dralka@gmail.com.

Medulloblastoma is a common term used for the juvenile malignant brain tumor, and its treatment is exciting due to different genetic origins, improper transportation of drug across the blood-brain barrier, and chemo-resistance with various side effects. Currently, medulloblastoma divided into four significant subsections (Wnt, Shh, Group 3, and Group 4) is based on their hereditary modulation and histopathological advancement. In this chapter, we tried to combine several novel chemical therapeutic agents active toward medulloblastoma therapy. All these compounds have potent activity to inhibit the medulloblastoma.

© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

DOI: 10.1007/978-1-0716-1952-0\_13  
PMID: 34978695